Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Karyopharm Therapeutics (KPTI) Leases (2019 - 2025)

Historic Leases for Karyopharm Therapeutics (KPTI) over the last 9 years, with Q4 2025 value amounting to $4.5 million.

  • Karyopharm Therapeutics' Leases fell 2270.56% to $4.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.5 million, marking a year-over-year decrease of 2270.56%. This contributed to the annual value of $4.5 million for FY2025, which is 2270.56% down from last year.
  • As of Q4 2025, Karyopharm Therapeutics' Leases stood at $4.5 million, which was down 2270.56% from $4.7 million recorded in Q3 2025.
  • Karyopharm Therapeutics' 5-year Leases high stood at $9.0 million for Q1 2021, and its period low was $2.6 million during Q3 2024.
  • Its 5-year average for Leases is $5.8 million, with a median of $5.6 million in 2023.
  • As far as peak fluctuations go, Karyopharm Therapeutics' Leases crashed by 4608.01% in 2024, and later skyrocketed by 8097.45% in 2025.
  • Karyopharm Therapeutics' Leases (Quarter) stood at $7.9 million in 2021, then dropped by 21.19% to $6.2 million in 2022, then tumbled by 31.45% to $4.3 million in 2023, then skyrocketed by 37.61% to $5.9 million in 2024, then decreased by 22.71% to $4.5 million in 2025.
  • Its last three reported values are $4.5 million in Q4 2025, $4.7 million for Q3 2025, and $5.1 million during Q2 2025.